State of New Jersey Common Pension Fund D Has $20.81 Million Holdings in Kenvue Inc. (NYSE:KVUE)

State of New Jersey Common Pension Fund D lifted its holdings in Kenvue Inc. (NYSE:KVUE) by 10.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 966,624 shares of the company’s stock after acquiring an additional 93,478 shares during the quarter. State of New Jersey Common Pension Fund D owned approximately 0.05% of Kenvue worth $20,811,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Clearstead Advisors LLC bought a new stake in shares of Kenvue in the third quarter worth about $25,000. Planned Solutions Inc. acquired a new stake in shares of Kenvue in the fourth quarter valued at approximately $27,000. EverSource Wealth Advisors LLC acquired a new stake in shares of Kenvue in the third quarter valued at approximately $28,000. AdvisorNet Financial Inc acquired a new stake in shares of Kenvue in the third quarter valued at approximately $28,000. Finally, Global Retirement Partners LLC acquired a new stake in shares of Kenvue in the third quarter valued at approximately $28,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 0.6 %

Shares of KVUE stock traded down $0.11 on Thursday, hitting $19.02. 14,246,216 shares of the stock were exchanged, compared to its average volume of 16,707,334. Kenvue Inc. has a one year low of $17.82 and a one year high of $27.80. The firm’s 50 day moving average is $19.84 and its two-hundred day moving average is $20.15. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. The company had revenue of $3.67 billion for the quarter, compared to analysts’ expectations of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. Kenvue’s quarterly revenue was down 2.7% on a year-over-year basis. On average, equities analysts expect that Kenvue Inc. will post 1.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on KVUE shares. Sanford C. Bernstein initiated coverage on shares of Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price on the stock. The Goldman Sachs Group initiated coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective for the company. William Blair initiated coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating for the company. JPMorgan Chase & Co. reduced their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 9th. Finally, Royal Bank of Canada reduced their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus price target of $24.85.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.